GRE
INVESTMENT ADVISORS LIMITED
We are a SFC licensed corporation in Hong Kong which provides Investment Advisory and Asset Management services,with a focus on alternative assets in the Asia Pacific region.
GRE
INVESTMENT ADVISORS LIMITED
本公司是一家获香港证券及期货事务监察委员会(SFC)发牌的持牌公司,提供投资顾问及资产管理服务,
重点关注亚太地区的另类资产。
ABOUT US
GRE
INVESTMENT ADVISORS LIMITED
GRE Investment Advisors Limited (“GRE”) is licensed by the Hong Kong Securities & Futures Commission (“SFC”) to provide investment advisory and asset management services, under type 4 (Advising on Securities) and Type 9 (Asset Management) licenses. The team is led by seasoned professionals with longstanding experience in the areas of investment management, investment banking and advisory in the Asia Pacific Region, including Greater China, Japan, Korea, Southeast Asia, Australia and India. Investor clients are typically institutional investors as well as ultra-highnet worth family offices looking for investment related services with deep local knowledge, network and investment expertise.
关于我们
GRE
INVESTMENT ADVISORS LIMITED
GRE Investment Advisors Limited(“GRE”)持有香港证券及期货事务监察委员会(“香港证监会”或“SFC”)颁发的第4类(就证券提供意见)及第9类(提供资产管理)牌照,可提供投资顾问及资产管理服务。 GRE团队由资深专业人士领导,在亚太地区的投资管理、投资银行及顾问服务领域拥有长期而丰富的经验,业务覆盖大中华区、日本、韩国、东南亚、澳大利亚及印度。 GRE的客户主要包括机构投资者及家族办公室,为其提供具备深厚本地市场知识、广泛业务网络及专业投资能力的投资相关服务。
PORTFOLIO
  • Animoca Brands
    Animoca is the leader in the emerging market of blockchain gaming and digital property rights based on NFTs (non-fungible tokens). The Company has a very successful portfolio of majority owned blockchain games and metaverses including the Sandbox, F1 Delta Time and RevvRacing. In addition, Animoca has over 100 strategic investments in relevant blockchain gaming and NFT projects.
    For more details,
  • Sirnaomics
    Sirnaomics is the first and only clinical-state RNA therapeutics biopharmaceutical company with a strong presence in both US and China through discovery and development of therapeutics for human disorders with unmet medical needs. The clinical development pipeline is focused on oncology and fibrosis indications. Sirnaomics was listed on the Hong Kong Stock Exchange on Dec 30, 2021 (HKSE stock code: 2257).
    For more details,
    please refer to https://sirnaomics.com
  • Genor Biopharma
    Genor Biopharma Company Limited (“Genor”) is a leading biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. Based in Shanghai, the Company was a spin-off from Walvax Biotechnology Company in June 2018 that was led by Hillhouse Capital and Hangzhou Tigermed Consulting.  Genor has successfully developed drug candidates targeting pathways with blockbuster potentials, encompassing top three oncology targets and five out of the ten bestselling drugs globally. Genor has established a pipeline of 15 targeted drug candidates with strong commercialization potentials in China that cover both proven and novel biological pathways. Genor currently has around 400 employees across 3 locations in China (Shanghai, Yunnan Yuxi and Beijing) as well as a lab in San Francisco, USA.
    For more details,
  • Carebridge
    The Company, operating under the brand JiaHui Health, is the leading premium health care service provider in China, with an anchor hospital platform in Shanghai.  It is the first foreign-funded premium private hospital which redefines international hospital standards in China, with six general clinics, over 300 full-time physicians and 100% premium insurance coverage.  It is the first top-tier private healthcare group with comprehensive specialties and capabilities.  The team is led by seasoned management with decades of experience, supported by blue chip shareholders. 
    For more details,
    please refer to https://www.jiahui.com
  • Cygnus Semiconductor
    The Company focuses on 5G/6G satellite internet, providing customers with competitive space-air-ground-sea integrated baseband chips and solutions for full-scenario applications.  The product portfolio covers 5G/6G eMBB, RedCap and NTN terminal/handset baseband chips and solutions.  The Company has a technical and product R&D team composed of seasoned industry experts, with extensive experience in cellular communications, satellite communications, chip design & verification, and mass production. Equipped with industry-leading chip design, simulation and verification tools, as well as a complete end-to-end wireless test environment, Cygnu Semi can independently execute the entire flow of large-scale chip design, verification and system testing.
    For more details,
    please refer to https://www.cygnusemi.com
  • VCredit
    Founded in 2006, VCredit is one of the pioneers of unsecured consumer credit in China. The Company has since grown into a leading on-line consumer credit company providing its users with a fully online credit services platform. VCredit was listed on the Hong Kong Stock Exchange on June 21, 2018 (HKSE stock code: 2003).
    For more details,
  • Tuhu.cn
    The Company was founded in Shanghai in 2011 and is now the largest auto care e-commerce platform in China, providing customers with a comprehensive B2C auto-care services platform.
    For more details,
  • Mafengwo
    Founded in 2011, the Company is a leading online travel platform in China, providing users with trip planning advise and online booking service during their travel by a variety of user-generated contents and online merchants.
    For more details,
    please refer to http://www.mafengwo.cn/
  • Firmior AI
    The Company is an enterprise AI agentic system provider that builds, deploys and scales AI agents with security and sovereignty.  Its infrastructure services will initially focus on Greater China, Japan and Southeast Asia, where demand for sovereign AI infrastructure is particularly strong.  Its full-stack architecture has structural cost advantages via token optimization, backed by a team with proven experience in leading $200M+ prior revenue growth from AI products. 
    For more details,
投资案例
  • Animoca Brands
    Animoca Brands是基于NFT(非同质化代币) 的区块链游戏和数字产权新兴市场的领导者。该公司拥有非常成功的区块链游戏和元游戏组合,包括Sandbox,F1 Delta Time和RevvRacing等。此外,Animoca在相关区块链游戏和NFT项目中拥有百余项战略投资。
    更多详情,请参阅  https://www.animocabrands.com /
  • 圣诺医药
    通过发现和开发未满足医疗需求的人类疾病的治疗方法,圣诺医药是第一家也是唯一一家在美国和中国拥有强大影响力的临床状态RNA治疗的生物制药公司。该公司临床开发管线的重点方向是肿瘤和纤维化适应症类别。圣诺医药于2021年12月30日在香港联合交易所上市(香港证券交易所股票代码:2257)。
    更多详情,请参阅  https://sirnaomics.com
  • 嘉和生物药业
    嘉和生物药业有限公司(“嘉和”)是一家领先的生物制药公司,专注于肿瘤及自身免疫药物的研发和商业化。公司总部位于上海,由高瓴资本和杭州泰格医药科技股份有限公司主导,于2018年6月从云南沃森生物技术股份有限公司分拆成立。嘉和已成功研发出靶向通路且极具潜力的候选药物,涵盖全球前三大肿瘤靶标及十款畅销药物中的五款。嘉和已建立由15款靶向候选药物组成的产品管线,该等药物在中国具有巨大的商业潜力,涵盖已知及新型生物学通路。嘉和已在中国设立了三大办事处(上海、云南玉溪和北京),并在美国旧金山创立了实验室。公司目前拥有约400名员工。
    更多详情,请参阅  https://www.genorbio.com/cn/about-genor/
  • Carebridge
    Carebridge旗下以“嘉会医疗”(JiaHui Health)品牌运营,是中国领先的高端医疗服务提供商,并以上海的旗舰医院为核心平台。嘉会医疗是中国首家外资高端私立医院,致力于重新定义中国的国际化医院标准。目前已建立6家综合门诊,拥有超过300名全职医生,并实现高端商业医疗保险的全面覆盖。公司亦是中国首批具备完整专科设置及综合医疗服务能力的顶级私立医疗集团之一。公司管理团队经验丰富,核心成员在医疗及医院运营领域拥有数十年的行业经验,并获得多家蓝筹股东的支持。
    更多详情,请参阅  https://www.jiahui.com
  • Cygnus Semiconductor
    Cygnus Semiconductor专注于5G/6G卫星互联网领域,为客户提供具有竞争力的空天地海一体化基带芯片及全场景解决方案。公司的产品组合涵盖5G/6G eMBB、RedCap及NTN终端和手机基带芯片与解决方案。 公司拥有一支由资深行业专家组成的技术与产品研发团队,在蜂窝通信、卫星通信、芯片设计与验证以及量产等领域具备丰富经验。凭借行业领先的芯片设计、仿真与验证工具,以及完整的端到端无线测试环境,Cygnus Semiconductor能够独立完成大规模芯片设计、验证及系统测试的全流程。
    更多详情,请参阅  https://www.cygnusemi.com
  • 维信金科
    维信金科成立于2006年,是中国消费信贷的探索者。该公司已经成长为一家领先的在线消费金融公司,为其用户提供全面的在线信贷服务。 维信金科已于2018年6月21日在香港证券交易所上市(股票代码:2003)。
    更多详情,请参阅  https://www.vcredit.com/about-us/about-us/
  • 途虎养车
    途虎养车于2011年成立于上海,目前是中国最大的汽车养护电商平台,为用户提供全面的B2C汽车养护服务。
  • 马蜂窝
    马蜂窝成立于2011年,是中国领先的在线旅游社区之一。马蜂窝通过用户原创内容和其线上电商服务,为用户提供旅游规划建议和在线预订。
    更多详情,请参阅  http://www.mafengwo.cn/
  • Firmior AI
    Firmior AI是一家企业级智能体系统提供商,致力于帮助企业安全、自主地构建、部署并规模化应用AI智能体。公司的基础设施服务初期将重点覆盖大中华区、日本及东南亚等市场,这些地区对自主可控AI基础设施的需求尤为旺盛。凭借全栈式技术架构及Token优化能力,公司在运营成本方面具备结构性优势。其核心团队拥有成熟的AI产品商业化经验,曾推动相关AI产品实现超过2亿美元的收入增长。
SERVICES

We provide investment advisory and asset management services to institutions and ultra-high net worth individuals. as well as family offices from Asia and from Europe.  Investments of focus include private equity, private equity funds, hedge funds, special credit and fixed income in the Asia Pacific Region, including Greater China, Japan, Korea, Southeast Asia, Australia and India.

We are an Advisor to NM Strategic Management, LLC, the investment manager of the various NM Strategic Focus Funds. NM Strategic Focus Funds are private equity Funds with a focus on making growth equity direct investments in the areas of consumer technology and services, fintech, healthcare, AI and other new technology sectors in the Greater China and Asia Pacific regions.

We are also the Investment Advisor to QLA Investment SCSp, a fund of private equity funds platform backed by prominent families from Europe. QLA Investment SCSp is focused on the mid-market buyout and growth space in the Asia Pacific region and invests across primary LP commitment, LP secondaries, continuation vehicles and co-investment strategies. QLA Investment SCSp has built partnerships with five private equity managers in Australia, three in Southeast Asia/South Asia and two in North Asia.

服务

本公司为机构投资者、超高净值人士,以及来自亚洲和欧洲的家族办公室提供投资顾问及资产管理服务。重点关注的投资类别包括亚太地区的私募股权、私募股权基金、对冲基金、特殊信贷及固定收益投资,覆盖大中华区、日本、韩国、东南亚、澳大利亚及印度。

本公司担任NM Strategic Management, LLC的投资顾问。NM Strategic Management, LLC是多个NM Strategic Focus Funds的投资管理人。NM Strategic Focus Funds为私募股权基金,主要在大中华区及亚太地区对消费科技与服务、金融科技、医疗健康、人工智能(AI)及其他新兴科技领域的成长型企业进行直接股权投资。

本公司担任QLA Investment SCSp的投资顾问。QLA Investment SCSp是一家获得欧洲知名家族支持的私募股权母基金投资平台。该基金专注于亚太地区中端市场的并购及成长型投资机会,投资策略涵盖私募股权基金一期份额认购、LP份额二级交易、接续基金及共同投资。截至目前,QLA Investment SCSp已与多家亚太地区私募股权管理人建立合作关系,包括澳大利亚5家、东南亚及南亚3家,以及北亚2家。

MANAGEMENT TEAM
  • Mr. Yip is the managing director and responsible officer of GRE Investment Advisors Limited, a Hong Kong Securities and Futures Commission licensed advisor to NM Strategic Management, LLC, which manages NM Strategic Focus Fund I and II, investing in private equity situations in the Greater China region. GRE is also a licensed manager to QLA Investment GP SÀRL, a fund of private equity funds platform backed by prominent families from Europe , and an independent non-executive director of CSI Properties Limited (497 HK) and a member of its nomination committee.

    Mr. Yip has been an independent non-executive director of Shun Tak Holdings Limited (publicly listed on the Main Board of the HK Stock Exchange, 242 HK) since October 2015, and is a member of the audit and risk management committee and a member of the nomination committee and remuneration committee. Mr. Yip is also a non-executive director and a member of the audit committee of VCREDIT Holdings Limited (publicly listed on the Main Board of the HK Stock Exchange, 2003 HK).

    Mr. Kevin Yip has extensive experience in private equity, alternative and portfolio investment.  He was previously managing director and responsible officer of Bosera Asset Management (International) Co., Limited in Hong Kong.  Prior to that he was a founding and senior partner of General Enterprise Management Services (HK) Limited, a private equity management company.  He was previously a vice president of JP Morgan International Capital Corporation.

    Mr. Kevin Yip is currently a member of the Investment Advisory Committee of EQT, a leading global private equity group with over US$300 billion in total assets under management, which works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

    Mr. Kevin Yip holds an A.B. Degree in Economics (magna cum laude) from Harvard University, and is currently a member of Dean’s Asia Advisory Committee of Harvard University’s Faculty of Arts and Sciences. He sits as a non-scientific member of the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster and is a member of the Routine and Expedited Panel of the Hospital Authority Central Institutional Review Board. He was chairman emeritus of the Hong Kong Venture Capital and Private Equity Association. He had also served on the Financial Services Advisory Committee of the Trade Development Council of the Hong Kong Special Administrative Region of the People’s Republic of China.

  • Mr. Woo is the Managing Director and Responsible Officer of GRE. Mr. Woo has 30 years of experience in the finance industry, specializing in the corporate finance and asset management.

    He was with JP Morgan for 15 years, holding various investment banking and asset management positions in Hong Kong and New York. He also held investment banking position with DBS Bank, as Managing Director and Head of DBS Asian Capital Ltd.

    Mr. Woo also had experience as a regulator for 3 years in Hong Kong, serving as an executive director of the Mandatory Provident Fund Schemes Authority. Mr. Woo is a Chartered Financial Analyst, and obtained a B.Sc degree from University of Calgary and an MBA from the University of Hong Kong.

  • Mr. Ng joined GRE as the CEO and NM Strategic Focus Funds as a Managing Partner in 2014. Mr. Ng has over nine years of Private Equity experience and over twenty years of Global Investment Banking experience spanning across Hong Kong, China, the Asia Pacific region, New York, Sydney and London.

    Before joining GRE and NM Strategic Focus Funds, Mr. Ng worked at J.P. Morgan for over 7 years and he was Chairman as well as the Head of J.P. Morgan's Asia Pacific Equity Capital and Derivatives Markets, focus on raising capital for both public and private companies via IPOs, Equity & Equity-linked Offerings as well as pre-IPO Private Placements. Prior to joining J.P. Morgan in 2006, Mr. Ng was at Merrill Lynch for over ten years and was Managing Director and the Head of Greater China Equity Capital Markets. Prior to that, he has also worked at UBS' Advisory & Financing Division in London and Goldman Sachs, Equity Capital Markets Division in London and Hong Kong.

    Throughout his Career, he has worked on some 500 equity and equity-linked transactions in the Asian Pacific region, including 250 transactions to raise over US$180 billion for Greater China Companies. In addition, he has worked on over 100 initial public offerings and pre-IPO placements, raising over US$100 billion for Asian companies listed on the major stock exchanges globally (Hong Kong, NYSE, NASDAQ, London, Singapore, Tokyo etc.). He recently completed the landmark US$23 billion VinFast Auto NASDAQ DeSPAC IPO in August 2023.

    Besides his global Capital Markets roles at J.P. Morgan, he has served as a Board of Director for both J.P Morgan Securities (Asia Pacific) Limited and J.P. Morgan Broking (Hong Kong) Limited. He also served as a member of JP Morgan’s Global Managing Director promotion committee, responsible for approving candidates worldwide to be promoted to Managing Directors. In additional, he was a member of the J.P. Morgan Asia Pacific Equity Commitment Committee which is responsible for vetting and approving all of J.P. Morgan's equity & equity linked transactions across the Asia Pacific Region. He also previously served as a Hong Kong SFC Responsible Officer as well as a Hong Kong Monetary Authority Executive Officer.

  • Mr. Cary Zhou is a partner of GRE and previously served as a Senior Partner with New Margin Ventures since 2007.

    For over the years, Mr. Zhou has worked throughout China beginning with AT&T Bell Labs as senior engineer for telecommunications, followed by a move to Lucent Technology (China) resulting in his role as a Vice President of Sales & Marketing. At Lucent, he was the Chief Representative of Lucent Technology for southern China, where he was responsible for the oversight of all of Lucent's activities in the region, including with respect to government relationships. Mr. Zhou also set up the Lucent Joint Venture in China and was the General Manager for Lucent Technologies of Shanghai Joint Venture.

    Mr. Zhou received his B.S. and M.S. degrees in Electrical Engineering from the Polytechnic University of New York. He has industry background, extensive government relationships in China, experience with publicly traded companies and demonstrated business expertise.

  • Mr. Ho joined GRE as our Chief Financial and Compliance Officer in June 2022.  Mr. Ho has over 25 years of experience in audit, finance, compliance, and fund investment and administration experience. 

    Mr. Ho was the Controller/CFO and Executive Director for more than 10 years of several investment funds including hedge fund, real estate fund and private equity fund. During this period, Mr. Ho also served as the Financial Controller and Company Secretary of several Hong Kong listed companies to handle statutory financial reporting, compliance with the SFC and HK listing rules.

    Prior to that, he worked for Resources Global Professionals in Hong Kong, the PRC, and Tokyo, Japan as a Consultant, assisting clients on accounting, merger and acquisitions and financial due diligence in Hong Kong, the PRC and Tokyo, Japan.

    Prior to Resources Global Professionals, Mr. Ho was the Finance Manager of Simplex Capital Asia Limited, which involved direct investments in Hong Kong and the PRC.  Mr. Ho’s main responsibilities included management reporting, company secretarial work, compliance with regulating authorities and analyzing and monitoring the financial position of the fund's direct investments.  Prior to Simplex Capital Asia, he was stationed in Shenzhen & Guangzhou as an Audit Senior with Arthur Andersen & Co.  Mr. Ho began his career as an auditor for Ernst & Young in Hong Kong.

    Mr. Ho received a B.A. (Hons) Degree in Accountancy from Hong Kong Polytechnic University.   He is a Fellow Member of The Association of Chartered Certified Accountants (FCCA) and an Associate Member of the Hong Kong Institute of Certified Public Accountants (CPA).

  • Mr. Xu is the Director of GRE and NM Strategic Focus Fund L.P. He joined NM Strategic Partners, which is an independent USD GP sponsored by the NewMargin Group, since 2015. Before NewMargin, He was working as an auditor in Deloitte from 2010, mainly serving companies listed in US or compliance with US GAAP.

    Mr. Xu received his bachelor’s degree of Economics from the Shanghai University of Finance and Economics (2006-2010), as well as a diploma of Finance and Economics from the University of Southampton (2008-2009). Mr. Xu mainly focuses on TMT related sectors and AI at growth stage in China. Mr. Xu has earned the Chartered Financial Analyst (CFA) designation.

  • Mr. Chen is an Associate Director of GRE. Prior to joining GRE, Mr. Chen worked as an investment professional at Goldman Sachs Asset Management. In this role, he covered primary, secondary, and co-investment opportunities in the private equity space. Before Goldman Sachs, Mr. Chen worked at the investment banking division of Credit Suisse. There, he advised financial sponsors on mergers and acquisitions and leveraged finance transactions in Asia Pacific.

    Mr. Chen received his bachelor’s degree of Economics from the Remin University of China and his master’s degree of Science from Columbia Business School.

  • Mrs. Gong serves as an Vice President of GRE. Prior to joining GRE, Mrs. Gong has 6-year working experience in the private equity sector, focusing on post-investment management and fund operation.

    Mrs. Gong was previously an auditor at PWC, focusing on the private equity and mutual fund sector. During that period, she provided assurance service, including statutory audit and internal control services, to over 30 funds across China.

    Mrs. Gong received her bachelor’s degree of Economics from Shanghai University of Finance and Economics in 2011.

  • Mr. Zhuo is a venture partner of GRE and a founding partner of V-star Capital. Before V-star, Mr. Zhuo served as a partner in New Margin Ventures from 2009 to 2017. Prior to New Margin, he worked for J.P Morgan Securities (Asia Pacific) Limited for 5 years, participating in a series of global IPOs and M&A for Chinese companies.

    Mr. Zhuo received his bachelor’s degree in International Securities, Investment and Banking (ISIB) from ICMA Centre, the University of Reading.

  • Mr. Tsang is an Associate of GRE. Prior to joining GRE, Mr. Tsang was an Associate at Sumitomo Mitsui Trust where he covered private equity fund investments and co-investments. Before Sumitomo Mitsui Trust, he worked at TR Capital, focusing on private equity secondaries investments.

    Mr. Tsang received his bachelor’s degree of Quantitative Finance from the Hong Kong University of Science and Technology.

管理团队
  • 叶家祺先生是GRE Investment Advisors Limited的董事总经理及负责人员。该公司是香港证券及期货事务监察委员会持牌机构,担任NM Strategic Management, LLC(管理专注于投资大中华区私募股权项目的NM Strategic Focus Fund I及II基金)的持牌顾问,同时亦是QLA Investment GP SÀRL(由欧洲显赫家族基金支持的私募母基金平台)的持牌管理人,并担任资本策略地产有限公司(CSI Properties Limited,股份代码:497.HK)的独立非执行董事及其提名委员会成员。

    叶先生自2015年10月起担任信德集团有限公司(香港联合交易所主板上市,股票代码242)的独立非执行董事,并兼任审核及风险管理委员会、提名委员会与薪酬委员会成员。他同时担任维信金科控股有限公司(香港联合交易所主板上市,股票代码2003)的非执行董事及公司审核委员会成员。

    叶先生在私募股权、另类投资及组合投资领域拥有丰富经验。曾任博时基金(国际)有限公司香港地区的董事总经理及负责人员,此前是私募投资管理机构湛思投资管理(香港)有限公司的创始人及高级合伙人,更早前曾担任摩根大通国际资本公司的副总裁。

    叶先生现任全球领先私募集团殷拓集团(管理资产规模超3000亿美元)的策略投资委员会成员,该集团通过赋能被投企业实现可持续增长、运营卓越及维持市场领导地位。

    叶先生持有美国哈佛大学经济学文学士学位(优等成绩毕业),现任哈佛大学文理学院院长在亚洲的咨询委员会成员,兼任香港大学/医管局港岛西医院联网研究伦理委员会非医疗卫生成员、医管局中央研究伦理委员会常规与快速审查小组成员。他曾获香港创业及私募投资协会荣誉主席衔,并曾任中华人民共和国香港特别行政区贸易发展局金融服务咨询委员会成员。

  • 吴积民先生是GRE的常务董事兼负责人。吴先生在金融行业有30年的从业经验,专注于企业理财和资产管理。

    吴先生在摩根大通工作了15年,曾在香港和纽约担任众多投资银行和资产管理的职位。他还曾在星展银行担任其亚洲资本有限公司董事总经理及主管。

    吴先生亦曾在香港监管机构从业3年,担任强制性公积金计划管理局(Mandatory Provident Fund Schemes Authority)的执行董事。 吴先生是一名特许金融分析师,并获得加拿大卡尔加里大学理学学士学位及香港大学工商管理硕士学位。

  • 吴绳祖先生于2014年加入GRE担任首席执行官,并在上海永宣创业投资管理有限公司(NM Strategic Focus Funds) 担任管理合伙人。吴先生拥有超过9年的私募股权经验和超过20年的全球投资银行经验,遍及中国香港、中国内地、亚太地区、纽约、悉尼和伦敦。

    在加入GRE和上海永宣之前,吴先生在摩根大通工作了7年多,是摩根大通亚太区股权资本和衍生品市场部门的主席以及部门主管,专注于通过首次公开发行(IPO)、股权和股权相关产品、首次公开募股前配售等方式为上市和私营企业筹集资金。在2006年加入摩根大通之前,吴先生在美林证券(现美银美林)有十余年工作经验,并曾任美林大中华区股权资本市场董事总经理兼大中华区股权资本市场主管。在此之前,他还曾在瑞银伦敦的咨询与融资部门、以及高盛伦敦和香港的股权资本市场部工作。

    在吴绳祖先生的职业生涯中,他参与了亚太地区约500笔股权和股权相关交易,包括了为大中华区企业服务的约250笔交易,为这些公司筹集了约1800亿美元的资金。此外,他还参与了100多家在全球主要证券交易所(香港、纽约、纳斯达克、伦敦、新加坡、东京等证券交易所)上市的亚洲公司的首次公开募股和首次公开募股前的配售,筹集了超过1000亿美元的资金。他最近于2023年8月完成了具有里程碑意义的230亿美元的VinFast Auto 在纳斯达克的DeSPAC 的 IPO。

    除了在摩根大通担任全球资本市场的职务外,他还曾担任摩根大通证券亚太有限公司以及摩根大通期货香港董事会的董事。他还曾担任摩根大通全球董事总经理晋升委员会的成员,负责批准全球候选人晋升为董事总经理。另外,他也是摩根大通亚太区股权承诺委员会的成员,该委员会负责审批摩根大通在亚太区的所有股权和股权相关交易。此外,他亦曾担任香港证监会的负责官员及香港金融管理局执行官。

  • 周永凯先生是GRE的合伙人。

    自2007年以来,他也曾担任上海永宣创业投资管理有限公司(NewMargin Ventures)的高级合伙人。多年来,周先生一直在中国各地工作。周先生的职业生涯从在美国电话电报公司贝尔实验室(AT&T Bell Labs)担任电信高级工程师开始,后来进入朗讯科技(中国)担任销售和营销副总裁。

    他是朗讯技术中国华南地区的首席代表,负责监督朗讯在该地区的所有活动,其中包括与政府关系的处理。周先生还在中国设立合资企业,并担任朗讯上海合资企业的总经理。

    周先生持有纽约理工大学电气工程学学士和硕士学位。他在中国有广泛的行业背景和政府关系,以及与各类上市公司的合作经验。

  • 何知源先生于2022年6月加入GRE担任首席财务官和合规总监。何先生在审计、财务、合规、基金投资和行政方面拥有超过25年的工作经验。

    何先生曾在数家投资基金累计超过10年担任财务总监/ 首席财务官和执行董事的角色,包括对冲基金、房地产基金和私募股权基金。在此期间,何先生还曾担任多家香港上市公司的财务总监和公司秘书,处理法定财务报告,合规遵守香港证监会和上市规则。

    在此之前,他曾在香港、中国大陆和日本东京的Resources Global Professionals担任顾问,协助客户在香港、中国大陆和日本东京当地的会计、并购和财务尽职调查。

    在加入Resources Global Professionals之前,何先生是先策投资亚洲有限公司的财务经理,该公司涉及在香港和中国大陆的直接投资。何先生的主要职责包括管理报告、公司秘书工作、遵守监管部门的规定以及分析和监督该基金直接投资的财务状况。在加入先策投资亚洲有限公司之前,他在深圳及广州安达信公司担任高级审计师。何先生职业生涯的最初是一名香港安永会计师事务所的审计师。

    何先生持有香港理工大学会计(荣誉)学士学位。他是英国特许公认会计师公会(FCCA)的资深会员及香港会计师公会(CPA)的会员。

  • 许晓辰先生是GRE的董事。自2015年起,他加入了上海永宣创业投资管理有限公司(NewMargin Ventures)的独立的美元基金团队。在上海永宣之前,他自2010年起在德勤担任审计师,主要服务于在美国上市或符合美国公认会计准则的中国企业。

    许先生获得上海财经大学经济学学士学位(2006-2010),及英国南安普顿大学金融经济学学位证书(2008-2009)。许先生主要专注于中国互联网相关行业以及人工智能方向的投资及研究。许先生是一名注册金融分析师(CFA)。

  • 陈明先生是GRE的副董事。在加入GRE之前,他在高盛资产管理部门的投资团队,参与私募股权领域母基金、S基金和跟投的交易。陈先生也曾在瑞士信贷投资银行部门工作,参与私募股权基金相关的兼并收购和杠杆贷款交易。

    陈先生获得中国人民大学经济学学士学位及哥伦比亚大学商学院理学硕士学位。

  • 龚晓蓉女士担任公司副总裁职位。在加入GRE之前,龚女士在私募股权领域有6年的工作经验,专注于投后管理和基金运营。

    龚女士曾在普华永道担任审计师,专注于私募股权和共同基金领域。在此期间,她为全国30多家私募和公募基金提供保证服务,包括法定审计和内部控制。

    龚女士于2011年获得上海财经大学经济学学士学位。

  • 卓星煜先生是GRE的风险合伙人及源星资本的创始合伙人。

    在创立源星资本之前,卓先生曾于2009至2017年担任上海永宣创业投资管理有限公司(NewMargin Ventures)的合伙人。在上海永宣之前,他在摩根证券(亚太)有限公司工作5年,参与过一系列中国企业在全球IPO和并购活动。

    卓先生于英国雷丁大学国际金融市场管理中心获得国际证券、投资及银行学学士学位(ISIB)。

  • 曾杰先生是GRE的投资经理,在加入GRE之前,他在三井住友信託担任投资经理,参与私募股权基金投资和跟投交易。在此之前,曾先生在TR Capital工作,参与私募股权的S基金交易。

    曾先生获得香港科技大学量化金融学学士学位。

CONTACT
ADDRESS
Principal Place of Business
2201 Bank of America Tower,
12 Harcourt Road,
Central,
Hong Kong
 
Suite 25066, K Wah Center,
1010 Middle Huahai Road,
Shanghai, China
Telephone & Fax
Tel: +852 2360 2798
Fax: +852 2360 2799
Email
Brian Ho:bho@gre-inv.com
Kester Ng: kng@gre-inv.com
© GRE INVESTMENT ADVISORS LIMITED. All rights reserved.
联系我们
公司地址
香港中环夏𢡱道12号美国银行中心2201室
上海市淮海中路1010号嘉华中心2506室
电话和传真
电话: +852 2360 2798
传真: +852 2360 2799
电子邮件
何知源:bho@gre-inv.com
吴绳祖: kng@gre-inv.com
© GRE INVESTMENT ADVISORS LIMITED. All rights reserved.
EN / 中文